Anzeige
Mehr »
Login
Mittwoch, 29.05.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
Künstliche Intelligenz lässt die Nachfrage explodieren - so profitieren Anleger
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P200 | ISIN: KYG0146B1032 | Ticker-Symbol: 4RY
Frankfurt
29.05.24
08:59 Uhr
3,740 Euro
-0,260
-6,50 %
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
AKESO INC Chart 1 Jahr
5-Tage-Chart
AKESO INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,6603,80014:05
3,6403,88014:07

Aktuelle News zur AKESO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiJPM Keeps Rating at Overweight for AKESO , Sees Correction as Buying Opportunity1
FrChina's Akeso plunges as drug's clinical trial results seen below expected2
FrAKESO (09926): VOLUNTARY ANNOUNCEMENT (IVONESCIMAB INJECTION) OBTAINED NMPA'S MARKETING APPROVAL IN CHINA3
FrBiopharmas Slump; AKESO Cascades 39%; BEIGENE Dives 8%2
29.04.AKESO (09926): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED HOLDERS - NOTICE OF PUBLICATION OF 2023 ANNUAL REPORT1
29.04.AKESO (09926): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF 2023 ANNUAL REPORT1
29.04.AKESO (09926): 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT-
29.04.AKESO (09926): 2023 ANNUAL REPORT1
24.04.AKESO (09926): VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATION FOR CADONILIMAB (PD-1/CTLA-4) ...1
08.04.Akeso, Inc.: Oral report | The positive interim analysis results from the Phase III clinical study of Akeso's Cadonilimab (PD-1/CTLA-4 BsAb) plus chemotherapy as first-line treatment for advanced gastric cancer presented at 2024 AACR55SAN DIEGO, April 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the positive interim analysis results from Phase III clinical study of Cadonilimab (PD-1/CTLA-4 BsAb) combined...
► Artikel lesen
08.04.AKESO (09926): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS-
08.04.AKESO (09926): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS-
28.03.AKESO (09926): NEXT DAY DISCLOSURE RETURN1
28.03.AKESO (09926): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE1
28.03.Akeso marks profit milestone with swift rights issue2
21.03.Biological products developer Akeso falls on discounted share sale1
21.03.AKESO (09926): PLACING OF NEW SHARES UNDER GENERAL MANDATE1
20.03.Citi raises Akeso (09926) to HKD64 1
18.03.AKESO (09926): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023-
06.03.Akeso, Inc.: Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-line Treatment of PD-L1 negative NSCLC61HONG KONG, March 6, 2024 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced the enrollment of the first patient in the registrational Phase III clinical study comparing Cadonilimab (PD-1/CTLA-4...
► Artikel lesen
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1